Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 344.74M P/E - EPS this Y - Ern Qtrly Grth -
Income -42.21M Forward P/E -8.04 EPS next Y - 50D Avg Chg 8.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 69.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -25.00%
Recommedations 3.00 Quick Ratio 6.61 Shares Outstanding 55.23M 52W Low Chg 514.00%
Insider Own 70.38% ROA -39.75% Shares Float 16.31M Beta -
Inst Own 8.13% ROE -200.47% Shares Shorted/Prior 2.91M/2.50M Price 7.24
Gross Margin - Profit Margin - Avg. Volume 145,532 Target Price -
Oper. Margin - Earnings Date May 7 Volume 125,637 Change -1.50%
About Pulse Biosciences, Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Pulse Biosciences, Inc News
07:00 AM Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
04/24/24 Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
04/01/24 Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript
03/29/24 Q4 2023 Pulse Biosciences Inc Earnings Call
03/28/24 Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023
03/28/24 Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
03/28/24 Pulse Biosciences Announces Plans to Initiate a Rights Offering
03/14/24 Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
03/08/24 Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
02/14/24 Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
09:53 AM Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth
01/31/24 Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
01/06/24 Insiders of Pulse Biosciences, Inc. (NASDAQ:PLSE) must be disappointed as stock fell 26% after recent purchases
08:00 AM Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
12/20/23 Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
12/03/23 Executive Chairman of Pulse Biosciences Robert Duggan Buys More Stock
11/21/23 Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
11/18/23 Chief Strategy Officer of Pulse Biosciences Picks Up 24% More Stock
11/15/23 Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
11/14/23 Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Call Transcript
PLSE Chatroom

User Image Stock_Titan Posted - 1 hour ago

$PLSE Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 https://www.stocktitan.net/news/PLSE/pulse-biosciences-announces-timing-of-rights-offering-for-up-to-60-n2ltk61m4244.html

User Image TruthBroker2 Posted - 20 hours ago

$PLSE Next Week Gonna be Good 👍

User Image TruthBroker2 Posted - 04/30/24

$SMMT $PLSE

User Image TruthBroker2 Posted - 04/30/24

$PLSE It's Happening back to 10 LFG Team Pulse

User Image TruthBroker2 Posted - 04/28/24

$SMMT $PLSE

User Image TruthBroker2 Posted - 04/27/24

$PLSE

User Image TruthBroker2 Posted - 04/26/24

$PLSE

User Image GI197845 Posted - 04/25/24

$PLSE Well, it's at 666 so that's good,. The first 6 represents the anti-christ (fake-false, christ) the second 6 represents the false prophet and the third 6 represent the beast. Or, 6"tall, 6 figure income and at least 6 inches in the pants if you want to satisfy female hypergamy.

User Image HoHoHoHum Posted - 04/25/24

$PLSE rights offering record date not known yet. but first qtr earnings call date announced already. perhaps the eps could move up from here. staying long and strong.

User Image Stock_Titan Posted - 04/24/24

$PLSE Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 https://www.stocktitan.net/news/PLSE/pulse-biosciences-schedules-first-quarter-2024-financial-results-j6b3wdpmnrao.html

User Image TruthBroker2 Posted - 04/21/24

$PLSE

User Image JLongstreet Posted - 04/19/24

$PLSE must be getting close to the announcement for the offering, driving down the average price as much as possible

User Image GI197845 Posted - 04/19/24

$PLSE Do'h! How low can she go? Answer= Much, much lower!

User Image rangerhawkeye Posted - 04/15/24

$PLSE a rare green for me today

User Image HoHoHoHum Posted - 04/15/24

$PLSE announcement of record date for rights offering should be coming anytime.

User Image TruthBroker2 Posted - 04/15/24

$PLSE $SMMT

User Image TruthBroker2 Posted - 04/12/24

$PLSE

User Image TruthBroker2 Posted - 04/10/24

$PLSE

User Image GI197845 Posted - 04/09/24

$PLSE So, what are the upcoming catalysts, other than the dilutive shelf offering? Isn't PLSE waiting on another 510k approval?

User Image TruthBroker2 Posted - 04/08/24

$SMMT $PLSE

User Image RyanCintheBreeze Posted - 04/05/24

$PLSE $10 coming up. Long overdue for getting this product to market where it is needed. Speed test with benign lesions and arterial blockages, but the real market is surgical oncology. Excision while activating the body’s immune response!

User Image TruthBroker2 Posted - 1 month ago

$SMMT $PLSE

User Image GI197845 Posted - 1 month ago

$PLSE Do'h! My average PPS is 9.97! Don't dilute, don't do a steaming pile of shelf offer and please become ultra profitable asap.

User Image HoHoHoHum Posted - 1 month ago

$PLSE the record date for the offering has not been announced yet. but it is going to be some time in april. as soon as it is announced, one could reasonably expect the price to move up as market players start accumulating more shares to become eligible for more number of rights. conversely after the record date, there could be some unwinding of positions and a consequent price decrease. offer price itself will be based on the average price in the last 10 days before offer expiry. there are going to be some interesting price movements until this offering is completed. enjoy!!

User Image TruthBroker2 Posted - 03/31/24

$PLSE

User Image GI197845 Posted - 03/29/24

$PLSE I wonder when all of these technologies/products will be commercialized/sold? Is a profit on the near future, like this year? CellFX nsPFA Percutaneous Electrode will be commercialized/sold? CellFX nsPFA 360° Cardiac Catheter (End-effector of the proprietary designed and engineered CellFX nsPFA energy delivery system.) CellFX nsPFA Cardiac Clamp (End-effector of the proprietary designed and engineered CellFX nsPFA energy delivery system.)

User Image tradingtwenty Posted - 03/29/24

$PLSE has trended 76 times in the past 24 hours (based on 5 minute intervals). Latest press release on Mar 28, 2024 04:12 PM: Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results Link: https://tradingtwenty.com/news/410703/pulse-biosciences-reports-business-updates-and-fourth-quarter--full-year-2023-financial-results

User Image tradingtwenty Posted - 03/29/24

$PLSE has trended 63 times in the past 24 hours (based on 5 minute intervals). Latest press release on Mar 28, 2024 04:12 PM: Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results Link: https://tradingtwenty.com/news/410703/pulse-biosciences-reports-business-updates-and-fourth-quarter--full-year-2023-financial-results

User Image GI197845 Posted - 03/29/24

$PLSE Don't worry here here folks (bag holders) I have a very strong, gut feeling today that the PLSE stock price will remain so solid and in such a tight trend, that it will stay in this channel all day. Also, you have not lost anything until you've sold. Also, buy when there is blood in the streets. (Make sure to only apply this rule in the proper context, Buffet was not talking about Biotech/Penny-Stock-Start-Ups. Don't worry, the shelf offering is the smartest the PLSE could do, for growth to generate the money for sales. Now, in the future you might want to think twice about investing in a company that does not turn a profit...I should say no profits yet, but could make a profit.

User Image TruthBroker2 Posted - 03/29/24

$PLSE $SMMT

Analyst Ratings
Maxim Group Hold Sep 21, 22
HC Wainwright & Co. Neutral May 13, 22
Stephens & Co. Overweight Apr 1, 22
HC Wainwright & Co. Buy Apr 1, 22
HC Wainwright & Co. Buy Feb 10, 22
HC Wainwright & Co. Buy Nov 16, 21
Stephens & Co. Overweight Jul 27, 21
Maxim Group Buy Mar 11, 21
HC Wainwright & Co. Buy Jan 26, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DUGGAN ROBERT W Director Director Dec 12 Buy 9.15 17,999 164,691 36,984,179 12/14/23
DUGGAN ROBERT W Director Director Dec 11 Buy 9.36 90,118 843,504 36,966,180 12/13/23
DUGGAN ROBERT W Director Director Dec 08 Buy 9.54 116,656 1,112,898 36,876,062 12/12/23
DUGGAN ROBERT W Director Director Dec 07 Buy 9.19 74,852 687,890 36,759,406 12/11/23
DUGGAN ROBERT W Director Director Dec 06 Buy 9.06 82,813 750,286 36,684,554 12/08/23
DUGGAN ROBERT W Director Director Dec 06 Option 5.95 9,933 59,101 36,601,741 12/08/23
DUGGAN ROBERT W Director Director Dec 05 Buy 9.34 66,021 616,636 351,565 12/07/23
DUGGAN ROBERT W Director Director Dec 04 Buy 10.38 27,000 280,260 285,544 12/06/23
DUGGAN ROBERT W Director Director Dec 04 Option 10.66 40,347 430,099 36,591,808 12/06/23
DUGGAN ROBERT W Director Director Dec 01 Buy 9.07 45,600 413,592 258,544 12/05/23
DUGGAN ROBERT W Director Director Nov 30 Buy 9.06 152,944 1,385,673 212,944 12/04/23
DUGGAN ROBERT W Director Director Nov 29 Buy 9.33 218,600 2,039,538 60,000 12/01/23
DUGGAN ROBERT W Director Director Nov 29 Option 5.95 1,667 9,919 36,392,861 12/01/23
DUGGAN ROBERT W Director Director Nov 28 Buy 8.98 124,397 1,117,085 36,391,194 11/30/23
DUGGAN ROBERT W Director Director Nov 17 Buy 6.1 20,241 123,470 36,266,797 11/20/23
Danahy Kevin Patrick Chief Executive Offi.. Chief Executive Officer Nov 16 Buy 6.51 5,393 35,108 35,887 11/17/23
Levinson Mitchell E. Chief Strategy Offic.. Chief Strategy Officer Nov 15 Buy 5.91 17,800 105,198 1,039 11/17/23
Zanganeh Mahkam Director Director Nov 13 Option 2.14 76,075 162,800 604,911 11/15/23
DUGGAN ROBERT W Director Director Nov 07 Option 5.95 13,265 78,927 36,246,556 11/09/23
DUGGAN ROBERT W Director Director Aug 25 Option 5.95 1,667 9,919 36,233,291 08/28/23
DUGGAN ROBERT W Director Director Jul 25 Option 5.95 1,667 9,919 36,231,624 07/27/23
DUGGAN ROBERT W Director Director Jul 05 Option 3.41 132,133 450,574 36,229,957 07/07/23
DUGGAN ROBERT W Director Director May 09 Buy 6.51 10,022,937 65,249,320 30,414,661 05/10/23